Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132702 | 0.97 | HPGD (0.47) | HPGDRECQLEPHX1KDM4EPKM | |
| SCHEMBL6132348 | 0.96 | HPGD (0.46) | HPGDRECQLEPHX1KDM4EPKM | |
| SCHEMBL792038 | 0.91 | HPGD (0.49) | HPGDRECQLEPHX1KDM4EPKM | |
| SCHEMBL28683446 | 0.89 | HPGD (0.47) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL15362664 | 0.87 | HPGD (0.46) | HPGDRECQLEPHX1KDM4EPKM | |
| SCHEMBL5268640 | 0.87 | PDE4D (0.49) | HPGDRECQLEPHX1GPR119PDE4A | |
| SCHEMBL4219721 | 0.87 | HPGD (0.48) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL25960265 | 0.87 | HPGD (0.48) | HPGDRECQLEPHX1KDM4EGPR119 | |
| SCHEMBL21997478 | 0.86 | HPGD (0.47) | HPGDRECQLEPHX1KDM4EGPR119 | |
| SCHEMBL3701563 | 0.86 | HPGD (0.47) | HPGDRECQLEPHX1GPR119PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623914-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20240246916-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2024109684-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | 江苏亚虹医药科技股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-118059101-A | Use of 8-hydroxyquinoline derivatives | 江苏亚虹医药科技股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4349815-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117043141-A | 7-nitro-8-hydroxyquinoline derivative, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2022253152-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253152-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1173472-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246916-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF | CYP3A7, UGT1A7, UGT2B7 | HPGD 53/4885RECQL 120/4885EPHX1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.